Replies to post #122226 on Biotech Values

[oc631]

Unfortunately, no. The slide you cited makes it very clear that BCX5191 is a nucleoside, not a nucleotide. Such a design is obsolete (remember IDIX’s NM283?); I doubt that BCX5191 will make it into clinical trials.

It looks like Tibotec/Medavir are also working on a nucleoside inhibitor



http://viralmatters.blogspot.com/2011/06/medivirtibotecs-ns5b-inhibitor.html



Whether there's some unforeseen merit to the idea remains to be seen. Perhaps there's some IP licensing issues on HCV nucleotides which is moving the industry in this direction?